Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Canaline is a non-proteinogenic amino acid found primarily in legumes such as the jack bean (Canavalia ensiformis). Structurally related to ornithine but distinguished by an aminooxy group in its side chain, canaline acts as an irreversible inhibitor of the mitochondrial enzyme ornithine aminotransferase (OAT), a key enzyme in the urea cycle. By forming a stable oxime with pyridoxal 5′-phosphate at the OAT active site, canaline disrupts normal enzymatic function and interferes with nitrogen metabolism. Its toxicity is attributed both to this inhibition and to its incorporation into proteins via arginyl-tRNA synthetase, resulting in dysfunctional "canavanyl proteins." Canaline also inhibits other pyridoxal-dependent enzymes and can disrupt polyamine metabolism and generate reactive nitrogen species. It plays a role as a plant metabolite involved in chemical defense against insects[1][2][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on canaline.